Semaglutide weight loss before and after data from the STEP clinical trials show that adults on Wegovy 2.4 mg weekly lost an average of 12 to 15 percent of body weight over 68 weeks, compared with 2 to 3 percent on placebo. Individual outcomes vary widely based on dose adherence, diet, activity, and biology, and weight regain is common after stopping the drug.
What Clinical Trials Show
The STEP (Semaglutide Treatment Effect in People with Obesity) program is the most rigorous source of semaglutide weight loss data. STEP 1, published in the New England Journal of Medicine, enrolled 1,961 adults with a BMI of 30 or higher (or 27 with a weight-related comorbidity) without diabetes. Over 68 weeks, the semaglutide group lost an average of 14.9 percent of body weight, versus 2.4 percent on placebo. Roughly 69 percent of semaglutide users lost at least 10 percent of body weight, 51 percent lost at least 15 percent, and 32 percent lost at least 20 percent.
STEP 2 studied adults with type 2 diabetes and found slightly smaller weight loss, around 9.6 percent, reflecting the known challenge of losing weight with insulin resistance. STEP 3 combined semaglutide with intensive behavioral therapy and showed an average of 16 percent weight loss. STEP 4 examined what happens when semaglutide is stopped.
Typical Before-and-After Timeline
| Time on Semaglutide | Typical Dose | Average Weight Loss | What Users Commonly Notice |
|---|---|---|---|
| Weeks 1 to 4 | 0.25 mg | 1 to 2% | Reduced appetite, minor early loss |
| Weeks 5 to 8 | 0.5 mg | 3 to 5% cumulative | Clothes fitting looser, early plateau possible |
| Weeks 9 to 16 | 1 to 1.7 mg | 6 to 9% cumulative | Visible change in face and waist |
| Weeks 17 to 32 | 2.4 mg (maintenance) | 10 to 13% cumulative | Steepest weight loss phase |
| Weeks 33 to 68 | 2.4 mg | 12 to 15% cumulative | Slower loss, approach plateau |
The trajectory is not linear. Most users experience the steepest drop between months 3 and 9, followed by a gradual slowdown. A plateau around months 12 to 18 is common and does not necessarily indicate treatment failure.
Why Individual Results Vary So Much
Several factors explain the wide range of outcomes.
Dose and Adherence
Users who reach and maintain the 2.4 mg weekly dose lose substantially more weight than those who stay at lower doses. Missed doses, prolonged breaks, and inconsistent injection timing all reduce effectiveness. Dose tolerability drives a significant portion of the variance.
Diet Quality
Semaglutide reduces appetite but does not choose what you eat. Users who pair semaglutide with nutrient-dense, high-protein, fiber-rich meals tend to see better results. Those who rely on ultra-processed foods within their smaller appetite window may lose less weight or lose lean mass alongside fat. Guidance on our diet and nutrition hub aligns with these principles.
Physical Activity
Resistance training preserves lean mass during weight loss, improves metabolic health, and supports long-term maintenance. Sedentary users often lose more lean mass relative to fat, which can undermine body composition outcomes.
Starting Weight
Percent body weight lost is relatively consistent, but absolute pounds lost correlate with starting weight. Higher starting weights often produce larger visual before-and-after contrasts.
Biological Variation
Some individuals are non-responders, losing less than 5 percent body weight despite good adherence. Others are hyper-responders, losing 25 percent or more. Genetic factors, gut hormone baseline, and microbiome composition likely contribute, though predictive biomarkers are not yet clinically available.
What Before-and-After Photos Actually Show
Social media comparisons are motivating but not standardized. Lighting, posture, clothing, and time between photos all affect perceived change. Some photos reflect 6 months of therapy; others reflect 18 months. A few are compounded semaglutide or misattributed to the drug when lifestyle changes drove most of the result.
Clinical trial data is a more reliable benchmark for typical outcomes. Pair any social media reference with your own objective tracking: waist circumference, monthly weight, progress photos in consistent conditions, and lab markers like fasting glucose and A1C.
Side Effects That Can Affect Progress
Gastrointestinal side effects, primarily nausea, diarrhea, and constipation, affect 15 to 25 percent of users and can limit dose escalation. Reduced appetite is the therapeutic goal but can contribute to inadequate protein intake if not actively managed. Rapid weight loss also elevates the risk of gallstones, which may require gallbladder removal in a small minority of patients.
Less common but serious risks include pancreatitis, kidney injury from dehydration, and thyroid C-cell tumors (based on rodent data). The FDA’s drug safety resources track current warnings.
What Happens After Stopping Semaglutide
STEP 4 randomized participants who had lost significant weight on semaglutide to continue the drug or switch to placebo for another 48 weeks. Those who continued lost an additional 8 percent of body weight. Those who stopped regained roughly two-thirds of their previous loss within a year. This is not a failure of willpower but reflects the physiologic nature of obesity.
Current clinical guidelines from the American Diabetes Association and obesity medicine societies treat obesity as a chronic disease requiring ongoing management. Long-term semaglutide therapy is consistent with how hypertension or hyperlipidemia are managed with ongoing medication.
The Bottom Line
Semaglutide before and after clinical data show average weight loss of 12 to 15 percent over 68 weeks, with wide individual variation. The steepest loss occurs between months 3 and 9, followed by gradual slowing. Dose adherence, diet, activity, and biology all shape individual outcomes, and weight regain is common after stopping. Work with a clinician to set realistic goals and plan for long-term management.
Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions about a medical condition or treatment.
